Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain. Presentation Details: Abstract Title: Efficacy and safety of boten